23andMe shares somewhat better in trading debut after merger with Richard Branson SPAC
1 min readShares of 23andMe , the customer genetics enterprise that provides a dwelling DNA exam kit, have been slightly larger in their trading debut on Nasdaq Thursday, under the ticker “ME.” The business came to public marketplaces following merging with Richard Branson’s exclusive-reason acquisition company, or SPAC, VG Acquisition Corp. . SPACs, or blank-test providers, elevate money in an first public presenting and then have two several years to receive a organization or organizations. The auto became exceptionally preferred in 2020 during the pandemic and established data, although interest has dimmed in 2021. 23andMe was started in 2006 by Anne Wojcicki, Linda Avey and Paul Cusenza and presents people the prospect to have their genes examined, providing them with facts on overall health risks and ancestry. Consumers can buy one of the company’s examination kits, comprising a test tube for saliva selection that is then mailed to a laboratory for screening. The inventory was very last up .2% at $11. Current market Pulse Tales are Quick-fire, quick information bursts on stocks and marketplaces as they transfer. Visit MarketWatch.com for extra facts on this news.
